By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

According to the letter, the facility's methods, controls, and overall operations failed to comply with Current Good ...

USFDA issued a warning letter to Glenmark Pharmaceuticals for significant CGMP violations at its Pithampur plant, including ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have signed an exclusive licensing agreement for IGI's cancer treatment, adding to ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian biotechnology stocks, with some brokerages calling it the largest such deal ...

Glenmark Pharma Stocks Today, Glenmark Share Price Live Updates 11 July 2025: Shares of Glenmark Pharma in focus today. Here’s why Glenmark Pharma stock locked in upper circuit on the NSE at ₹2,094.40 ...

AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China ...

Shares of Glenmark Pharmaceuticals surged 14% to an all-time high on Friday after its biotechnology unit, Ichnos Glenmark Innovation (IGI), signed a landmark licensing deal with US drugmaker ...

Pharma giants like Cipla, Glenmark, and Emcure are stepping into the booming skincare market, challenging beauty brands with ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama maintains a more cautious outlook.

Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie for its early-stage blood cancer treatment.